Diamyd Medical

Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes. The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umea for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem...

Autoimune diabetes (type 1 diabetes and lada),pre-clinical and clinical development,development of combination therapies for the treatment of autoimmune diabetes,preserving beta cell function,pharmaceutical development,and targeted immunotherapy

Diamyd medical operates in the Pharmaceutical manufacturing industry.

Diamyd medical's revenue is < 1m

Diamyd medical has 11 - 50 employees.